WIXOM, Mich., March 5, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will host a Key Opinion Leader Breakfast on Thursday, March 6, 2014, beginning at 8:00am Eastern Time, in New York City. Rockwell's management team will provide a brief overview of the Company's strategies to drive long-term growth, and Key Opinion Leader, Anatole Besarb, MD, will discuss how Rockwell's Triferic™, currently under investigation for the treatment of iron replacement in dialysis patients, will play an integral role in the anemia and renal space.
Dr. Anatole Besarb is currently a Senior Director of Clinical Research at Fibrogen, Inc., and has an academic appointment as Consulting Professor of Medicine at Stanford University. He was previously Director of Clinical Research in the Division of Nephrology and Hypertension at Henry Ford Hospital, and was also Professor of Medicine at Thomas Jefferson University.
Dr. Besarb's research interest is in optimizing the management of anemia, which includes the use of different hematopoietic agents, with a focus on balancing iron and erythropoietic stimulating agents. He served as the Chair and the Co-Chair of the NKF Workgroup on Vascular Access as well as various committees for the FORUM of ESRD networks, including the ASN, NKF, ASAIO, and the NIH. He has authored more than 190 peer-reviewed papers, 28 chapters and 16 monographs.The presentations, followed by a Question-and-Answer session, will be webcast live beginning at 8am Eastern Time. To access the webcast, please go to the Investor Relations section of Rockwell's corporate website at www.RockwellMed.com . About Rockwell Medical Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV